NMN for Menopause: What the Evidence Actually Shows
What is Menopause?
Menopause is confirmed after 12 consecutive months without menstruation, typically around age 50. It brings hot flashes, vaginal dryness, sleep disruption and accelerated bone loss.
NMN relevance: the published evidence
Yoshino 2021 in postmenopausal women showed improved muscle insulin sensitivity at 250 mg/day but did not assess hot flashes, mood or bone density. Menopause-specific symptom relief has not been demonstrated. Hormone therapy remains the gold standard for moderate-to-severe symptoms.
Questions to ask before supplementing
250 mg/day per Yoshino 2021 (metabolic endpoints, not symptom relief).
Contraindications and red flags
Women with hormone-sensitive cancer history must clear any supplement with their oncologist.
Bottom line for Malaysian patients
NMN is not registered with NPRA as a treatment for any specific condition; it is sold as a general health supplement. If you have menopause, use this page as a question list for a registered medical practitioner before adding NMN to existing therapy. Read our safety guide for full red-flag context.
Related conditions
- Perimenopause - Perimenopause is the transition phase before menopause, marked by irregular cycles, hot flashes, sle...
- Osteoporosis - Osteoporosis is reduced bone density that raises fracture risk, especially of the hip, spine and wri...
- Biological Aging - Biological aging refers to the gradual decline in cellular and organ function that accompanies chron...
- Female Fertility Decline - Female fertility declines progressively from the early thirties as oocyte quality and quantity drop....